ATC Group: N06AX22 Agomelatine

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Nervous system
2
Psychoanaleptics
3
Antidepressants
4
Other antidepressants
5
N06AX22
Agomelatine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
25 mg

Active ingredients

Active Ingredient
Description

Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.

Medicines in this ATC group

Drug
Countries

Estonia Lithuania Poland

Poland

Estonia Lithuania Poland

South Africa

Poland

Austria Estonia Ireland Lithuania Poland ...

South Africa

Austria Brazil Cyprus Estonia Finland ...

South Africa

Austria Estonia Lithuania

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)